Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash from Financing Activities: 2014-2025

Historic Cash from Financing Activities for KalVista Pharmaceuticals (KALV) over the last 6 years, with Apr 2025 value amounting to $4.7 million.

  • KalVista Pharmaceuticals' Cash from Financing Activities fell 96.90% to $4.7 million in Q2 2025 from the same period last year, while for Apr 2025 it was $158.1 million, marking a year-over-year increase of 4.87%. This contributed to the annual value of $159.7 million for FY2025, which is 5.98% up from last year.
  • According to the latest figures from Q2 2025, KalVista Pharmaceuticals' Cash from Financing Activities is $4.7 million, which was up 1,479.32% from $295,000 recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Cash from Financing Activities ranged from a high of $150.1 million in Q2 2024 and a low of $128,000 during Q4 2023.
  • In the last 3 years, KalVista Pharmaceuticals' Cash from Financing Activities had a median value of $295,000 in 2024 and averaged $22.7 million.
  • As far as peak fluctuations go, KalVista Pharmaceuticals' Cash from Financing Activities skyrocketed by 1,370.59% in 2024, and later crashed by 96.90% in 2025.
  • KalVista Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at $128,000 in 2023, then soared by 130.47% to $295,000 in 2024, then slumped by 96.90% to $4.7 million in 2025.
  • Its last three reported values are $4.7 million in Q2 2025, $295,000 for Q4 2024, and $3.0 million during Q3 2024.